Literature DB >> 1989784

Deep venous thrombosis. Implications after open heart surgery.

G A DeLaria1, J A Hunter.   

Abstract

We reviewed the cases of 10,638 cardiac surgical patients to determine the incidence of deep vein thrombosis (DVT) after open heart surgery (OHS). Seventy-seven patients (0.7 percent) had DVT. Group 1 included 36 patients who had DVT without pulmonary embolism (PE). Occurrence was equal in either leg. Anticoagulation with heparin and warfarin sodium (Coumadin) was employed as treatment. Extension of hospital stay was 10.8 days. Group 2 consisted of 41 patients who experienced PE 9.9 days after OHS. Sixteen patients had known DVT and were receiving heparin. In 25 patients, PE was the first event. Risk factors for PE included perioperative myocardial infarction (16 percent), atrial fibrillation (41 percent); blood type A (70 percent) (p less than 0.05), and coronary artery bypass graft (CABG) (98 percent). Twenty-four patients were treated with anti-coagulation alone. Six died of recurrent PE; mortality was 25 percent. Seventeen patients received anticoagulation plus inferior vena cava (IVC) interruption using a Hunter balloon. There were no recurrent PEs and there was one death from myocardial infarction (6 percent). Deep vein thrombosis and PE are rare complications of OHS. Routine prophylaxis with either heparin or warfarin is unnecessary. Patients with DVT, atrial fibrillation (AF), and perioperative myocardial infarction are at high risk of PE. Aggressive diagnosis to identify major venous thrombi along with anticoagulation and early consideration of IVC interruption are recommended for these patients. Patients who have undergone OHS and who have PE are at an unusually high risk for recurrent PE with death and are more safely treated with IVC interruption and anticoagulation than anticoagulation alone.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1989784     DOI: 10.1378/chest.99.2.284

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Michael K Gould; David A Garcia; Sherry M Wren; Paul J Karanicolas; Juan I Arcelus; John A Heit; Charles M Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Risk and prophylaxis of catheter-related venous thromboembolism after cardiac surgery: where is the evidence?

Authors:  Davide Imberti
Journal:  Intern Emerg Med       Date:  2008-09-16       Impact factor: 3.397

3.  Prospective study of the value of necropsy examination in early death after cardiac surgery.

Authors:  A H Lee; B T Borek; P J Gallagher; R Saunders; R K Lamb; S A Livesey; V T Tsang; J L Monro
Journal:  Heart       Date:  1997-07       Impact factor: 5.994

4.  Incidence of Venous Thromboembolism after Sternal Reconstruction: A Single-center Retrospective Review.

Authors:  Allen F Yi; Kevin K Zhang; Sean D Arredondo; Andrew L O'Brien; Casey T Kraft; Jeffrey E Janis; Stephen J Poteet
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-08-16

5.  Deep venous thrombosis of the neck and pulmonary embolism in patients with a central venous catheter admitted to cardiac rehabilitation after cardiac surgery: a prospective study of 815 patients.

Authors:  Rino Frizzelli; Ornella Tortelli; Vincenzo Di Comite; Redenta Ghirardi; Claudio Pinzi; Cleante Scarduelli
Journal:  Intern Emerg Med       Date:  2008-03-21       Impact factor: 3.397

6.  Roburic Acid Targets TNF to Inhibit the NF-κB Signaling Pathway and Suppress Human Colorectal Cancer Cell Growth.

Authors:  Huanhuan Xu; Titi Liu; Jin Li; Fei Chen; Jing Xu; Lihong Hu; Li Jiang; Zemin Xiang; Xuanjun Wang; Jun Sheng
Journal:  Front Immunol       Date:  2022-02-09       Impact factor: 7.561

Review 7.  Incidence of Venous Thromboembolism and Benefits and Risks of Thromboprophylaxis After Cardiac Surgery: A Systematic Review and Meta-Analysis.

Authors:  Kwok M Ho; Ebrahim Bham; Warren Pavey
Journal:  J Am Heart Assoc       Date:  2015-10-26       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.